Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €21.19 EUR
Change Today +0.19 / 0.90%
Volume 207.5K
REC On Other Exchanges
REC is not on other exchanges.
As of 11:30 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

recordati spa (REC) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/15 - €24.04
52 Week Low
10/16/14 - €11.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RECORDATI SPA (REC)

Related News

No related news articles were found.

recordati spa (REC) Related Businessweek News

No Related Businessweek News Found

recordati spa (REC) Details

Recordati S.p.A. engages in the research, development, manufacture, marketing, and sale of pharmaceuticals. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, musculo-skeletal disorders and analgesia, pregnancy test, urology, OTC/non-prescription pharmaceuticals, allergy, antiinfectives, central nervous system, endocrinology, gastrointestinal, gynecology, obstetrics, nutrition and related areas, immunosuppressants, pediatrics, pneumology, hematology, oncology, respiratory, and generics. It primarily offers Zanidip (lercanidipine), a calcium channel blocker for the treatment of hypertension. The company’s product development pipeline includes Carbaglu, which is approved in the European Union and is under Phase III clinical trial in the United States for the treatment of organic acidemias; Zanipress that is approved in the European Union to treat essential hypertension; and Cystadrops that is under pre-registration in the European Union for the treatment of ocular cystinosis. Its product development pipeline also includes methadone that is under phase III b clinical trial to treat cancer related pain; Citrafleet, which is under Phase III clinical trials for colonoscopy; Graspa, which is under pre-filing stage in the European Union for acute lymphoblastic leukemia, as well as under phase II b clinical trials for acute myeloid leukemia; and REC 0438 that is under phase I clinical trial in the European Union for treating overactive bladder in patients with spinal lesions. Further, the company produces pharmaceutical chemicals, such as active pharmaceutical ingredients and intermediates. It has operations in Europe, Australasia, Africa, and the United States. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati SpA operates as a subsidiary of Fimei - Finanziaria Industriale Mobiliare ed Immobiliare S.P.A.

3,923 Employees
Last Reported Date: 03/6/15
Founded in 1926

recordati spa (REC) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €1.2M
Compensation as of Fiscal Year 2014.

recordati spa (REC) Key Developments

Recordati SpA Announces Consolidated Earnings Results for the Second Quarter and First Half Year Ended June 30, 2015

Recordati SpA announced consolidated earnings results for the second quarter and first half year ended June 30, 2015. For the quarter, the company has reported that revenue was EUR 263,314,000 compared to EUR 247,259,000 for the same quarter ended June 30, 2014. Operating income was EUR 71,754,000 compared with EUR 59,609,000 a year ago. Pretax income was EUR 67,279,000 compared with EUR 54,924,000 a year ago. Net income attributable to the equity holders of the parent was EUR 51,272,000 compared to EUR 40,278,000 for the same quarter ended June 30, 2014. For the six months, the company's reported revenue was EUR 539,060,000 compared to EUR 507,621,000 for the same quarter ended June 30, 2014. International sales, which represent 78.5% of total sales, grow by 10.0% while sales in Italy, at 21.5% of the total, decrease by 5.8%. Operating income was EUR 145,225,000 compared with EUR 121,796,000 a year ago. Pretax income was EUR 137,022,000 compared with EUR 113,024,000 a year ago. Net income attributable to the equity holders of the parent was EUR 103,236,000 compared to EUR 83,042,000 for the same quarter ended June 30, 2014. Diluted per share were EUR 0.494 compared with EUR 0.393 a year ago. EBITDA is EUR 163.9 million, an increase of 15.5% over the same period of the preceding year, with a margin of 30.4% of sales due to gross margin improvement and the relatively low increase in operational costs. Net financial position at 30 June 2015 records a net debt of EUR 139.9 million, a reduction of EUR 46.2 million compared to that at 31 December 2014.

Recordati SpA, H1 2015 Earnings Call, Jul 29, 2015

Recordati SpA, H1 2015 Earnings Call, Jul 29, 2015

Recordati SpA Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-09-2015

Recordati SpA Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-09-2015 . Venue: Terranea Resort, Rancho Palos Verdes, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REC:IM €21.19 EUR +0.19

REC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.133.50 CHF +2.90
Faes Farma SA €2.48 EUR +0.095
H Lundbeck A/S kr199.40 DKK +2.10
Shire PLC 4,899 GBp +16.00
Procter & Gamble Co/The $69.93 USD +0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation REC Industry Range
Price/Earnings 24.3x
Price/Sales 4.3x
Price/Book 5.0x
Price/Cash Flow 24.4x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECORDATI SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at